Yale Podnos - 14 Jul 2026 Form 4 Insider Report for Oncology Institute, Inc. (TOI)

Reporting relationship: Chief Medical Officer
Issuer ticker: TOI
Reported as of: 14 Jul 2026
Net transaction value: -$150,340
SEC form: 4
Accepted by SEC: 16 Jul 2026, 20:05:50 UTC
Prior SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Yale Podnos

Key filing fact

Yale Podnos filed Form 4 for Oncology Institute, Inc. (TOI) on 16 Jul 2026.

Key facts

This page summarizes Yale Podnos's Form 4 filing for Oncology Institute, Inc. (TOI).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Jul 2026, 20:05.

Change

Previous filing in this sequence was filed on 09 Jun 2026.
Current net transaction value: -$150,340.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001891104 Primary reporting owner

Podnos Yale

Relationship: Chief Medical Officer
Address: C/O THE ONCOLOGY INSTITUTE INC., 18000 STUDEBAKER RD, SUITE 800, CERRITOS
Signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Yale Podnos
Signature date: 16 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TOI transaction

Common Stock

Options Exercise

Transaction value
Shares: +17,974
Change %: +6.9%
Price: $1.87^*
Shares after: 277,501
Date: 14 Jul 2026
Ownership: Direct

TOI transaction

Common Stock

Sale

Transaction value: $115,555
Shares: -17,974
Change %: -6.5%
Price: $6.43
Shares after: 259,527
Date: 14 Jul 2026
Ownership: Direct
Footnotes: F1, F3

TOI transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,478
Change %: +2.1%
Price: $2.00^*
Shares after: 265,005
Date: 14 Jul 2026
Ownership: Direct

TOI transaction

Common Stock

Sale

Transaction value: $34,785
Shares: -5,478
Change %: -2.1%
Price: $6.35
Shares after: 259,527
Date: 14 Jul 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TOI transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: +17,974
Change %
Price: $1.87^*
Shares after: 0
Date: 14 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,974
Exercise price: $1.87
Footnotes: F2

TOI transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: +5,478
Change %
Price: $2.00^*
Shares after: 0
Date: 14 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,478
Exercise price: $2.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sale transactions were effected pursuant to a Rule 10(b) 5-1 trading plan adopted by the Reporting Person on 08/26/2025.

Footnote F2

The stock options described above were originally granted on 11/17/2022 and 05/21/2024, respectively, and vested in accordance with their respective terms.

Footnote F3

The sales reported in Table I reflect shares acquired upon exercise of the options identified in Table II, sold on the same day pursuant to the 10(b) 5-1 plan referenced in Footnote 1.